X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
breast cancer (10) 10
chemotherapy (10) 10
female (10) 10
humans (10) 10
index medicus (10) 10
middle aged (10) 10
adult (8) 8
breast neoplasms - drug therapy (8) 8
aged (7) 7
breast neoplasms - pathology (7) 7
cancer therapies (7) 7
trastuzumab (7) 7
analysis (6) 6
oncology (6) 6
antimitotic agents (5) 5
antineoplastic agents (5) 5
chemotherapy, adjuvant (5) 5
disease-free survival (5) 5
erbb-2 protein (5) 5
follow-up studies (5) 5
hematology, oncology and palliative medicine (5) 5
survival (5) 5
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
article (4) 4
cancer (4) 4
clinical trials (4) 4
internal medicine (4) 4
medicine, general & internal (4) 4
metastasis (4) 4
motivation (4) 4
research (4) 4
studies (4) 4
therapy (4) 4
trastuzumab - administration & dosage (4) 4
treatment outcome (4) 4
abridged index medicus (3) 3
antibodies, monoclonal - therapeutic use (3) 3
antibodies, monoclonal, humanized (3) 3
antibodies, monoclonal, humanized - administration & dosage (3) 3
antineoplastic agents - adverse effects (3) 3
antineoplastic agents - therapeutic use (3) 3
breast neoplasms - chemistry (3) 3
care and treatment (3) 3
combination (3) 3
drug therapy (3) 3
endocrine therapy (3) 3
epidermal growth factor (3) 3
heart diseases (3) 3
metastases (3) 3
neoplasm staging (3) 3
patients (3) 3
postmenopausal women (3) 3
radiation therapy (3) 3
receptor, erbb-2 - analysis (3) 3
surgery (3) 3
survival analysis (3) 3
survival rate (3) 3
toxicity (3) 3
tumors (3) 3
1-phosphatidylinositol 3-kinase (2) 2
adjuvant treatment (2) 2
aged, 80 and over (2) 2
antibodies, monoclonal - adverse effects (2) 2
antibodies, monoclonal, humanized - adverse effects (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
aspartate aminotransferase (2) 2
aspartate aminotransferases - blood (2) 2
biomarkers (2) 2
breast neoplasms - metabolism (2) 2
breast neoplasms - therapy (2) 2
combined modality therapy (2) 2
diarrhea (2) 2
docetaxel (2) 2
double-blind method (2) 2
drug administration schedule (2) 2
efficacy (2) 2
encephalopathy (2) 2
estrogen (2) 2
exanthema (2) 2
exanthema - chemically induced (2) 2
experiment (2) 2
heart diseases - chemically induced (2) 2
high energy physics (2) 2
lapatinib (2) 2
male (2) 2
mammography (2) 2
medical colleges (2) 2
medical prognosis (2) 2
multicenter (2) 2
mutation (2) 2
oncology, experimental (2) 2
open-label (2) 2
particle physics (2) 2
patient outcomes (2) 2
performance (2) 2
pertuzumab (2) 2
phase-ii (2) 2
physics (2) 2
plus (2) 2
post-menopause (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 3, pp. 236 - 244
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 7, pp. 904 - 916
Summary Background Phosphatidylinositol 3-kinase (PI3K) pathway activation is a hallmark of endocrine therapy-resistant, hormone receptor-positive breast... 
Hematology, Oncology and Palliative Medicine | HETEROGENEITY | WOMEN | PALBOCICLIB | THERAPY | EXEMESTANE | ONCOLOGY | MUTATION | RESISTANCE | COMBINATION | AROMATASE INHIBITORS | PI3K INHIBITOR | Estradiol - analogs & derivatives | Humans | Middle Aged | Aminopyridines - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Response Evaluation Criteria in Solid Tumors | Alanine Transaminase - blood | Receptors, Estrogen - analysis | Fulvestrant | Receptors, Progesterone - analysis | Breast Neoplasms - chemistry | Neoplasm Metastasis | Hyperglycemia - chemically induced | DNA, Neoplasm - blood | DNA Mutational Analysis | Exanthema - chemically induced | Postmenopause | Female | Morpholines - adverse effects | Aminopyridines - administration & dosage | Drug Eruptions - etiology | Double-Blind Method | Morpholines - administration & dosage | Estradiol - administration & dosage | Survival Rate | Signal Transduction - genetics | Breast Neoplasms - drug therapy | Phosphatidylinositol 3-Kinases - genetics | Disease-Free Survival | Retreatment | Breast Neoplasms - genetics | Class I Phosphatidylinositol 3-Kinases | Aspartate Aminotransferases - blood | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Aged | Biomarkers, Tumor - genetics | Receptor, ErbB-2 - analysis | Antimitotic agents | Medical colleges | Clinical trials | Product development | Breast cancer | Postmenopausal women | Hormones | Antineoplastic agents | Analysis
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9938, pp. 164 - 172
Journal Article
Lancet, The, ISSN 0140-6736, 2013, Volume 382, Issue 9897, pp. 1021 - 1028
Journal Article
Lancet, The, ISSN 0140-6736, 2007, Volume 369, Issue 9555, pp. 29 - 36
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 1, pp. 21 - 28
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 6, pp. 732 - 742
Summary Background The antibody–drug conjugate trastuzumab emtansine is indicated for the treatment of patients with HER2-positive metastatic breast cancer... 
Hematology, Oncology and Palliative Medicine | RECEPTOR | ONCOLOGY | PERTUZUMAB | DOCETAXEL | GUIDELINES | Capecitabine - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Response Evaluation Criteria in Solid Tumors | Antineoplastic Agents - therapeutic use | Hand-Foot Syndrome - etiology | Diarrhea - chemically induced | Young Adult | Breast Neoplasms - chemistry | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Lapatinib | Antibodies, Monoclonal, Humanized - adverse effects | Maytansine - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Maytansine - analogs & derivatives | Anemia - chemically induced | Survival Rate | Thrombocytopenia - chemically induced | Trastuzumab - administration & dosage | Breast Neoplasms, Male - drug therapy | Maytansine - therapeutic use | Breast Neoplasms - drug therapy | Breast Neoplasms, Male - chemistry | Disease-Free Survival | Retreatment | Taxoids - administration & dosage | Vomiting - chemically induced | Aspartate Aminotransferases - blood | Capecitabine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Quinazolines - adverse effects | Aged | Breast Neoplasms, Male - pathology | Receptor, ErbB-2 - analysis | Bridged-Ring Compounds - administration & dosage | Care and treatment | Breast cancer | Metastasis | Patient outcomes | Analysis
Journal Article
Lancet, The, ISSN 0140-6736, 2017, Volume 389, Issue 10075, pp. 1195 - 1205
Journal Article
Journal Article